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ABSTRACT 
 
 
 In cancer the immune system is activated in response to qualitative and quantitative 
aberrant expression by tumor cells of certain proteins named tumor-associated antigens 
(TAAs). In a previous study in the laboratory, has been investigated the presence of TAAs 
inducing auto-antibodies (auto-Abs) in the Colorectal cancer (Crc) by exploiting the patients 
serological reactivity against the surface membrane proteoma. Among several candidates, a 
specific immunoreactivity against A Disintegrin And Metalloprotease 10 (ADAM10) 
protein has been identify.ADAM10 is a disintegrin metalloprotease with a potential role in 
tumor progression and invasion due to its sheddase activity. ADAM10 is able to promote 
ERK1/2 signaling activation promoting cell proliferation by the cleavage of the extracellular 
domain (ECD) of the HER2 tyrosine kinase receptor, which is released in serum. Moreover, 
ADAM10 plays a critical physiological function in the epithelial morphogenesis since its 
sheddase activity is crucial for the cell migration and extracellular matrix (ECM) 
remodelling, a phenomenon that also drives tumor metastasis. Thus, an aberrant expression 
of the ADAM10 in epithelial tissues might elicit a specific serological immune response. 
The serological screening performed on purified ADAM10, showed a significant presence 
of immunoreactivity against ADAM10 in the sera from patients affected by tumors of 
epithelial origin like Crc, Pancreatic cancer (Pc) and Breast cancer (Brc) if compared with 
serological reactivity of healthy subjects. On the contrary, sera from patients affected by 
hematological malignancies such as chronic lymphocytic leukemia (B-CLL) and Multiple 
Myeloma (MM), did not showed significant immunoreactivity against ADAM10. These 
results suggested that the presence of auto-Abs against ADAM10 in patients sera might be a 
candidate biomarker for carcinomas of epithelial origin. Since it is known that ADAM10 is 
overexpressed in advanced stages of the Crc disease, when the lymph nodes are infiltrated  
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 by the tumor, we evaluated the disease course of this patients after surgical resection in 
order to define whether the presence of auto-Abs anti-ADAM10 is a favourable or 
detrimental signature, correlating the immunoreactivity with the patients follow-up. The 
results showed that the presence of auto-Abs anti-ADAM10 prolonged significantly the 
disease-free condition if compared with Crc patients without serological immunoreactivity 
against ADAM10. Thus, in order to investigate the effects of these auto-Abs, in vitro 
experiments of both HER2 ECD release and cell migration were performed using the Colon 
carcinoma cell line LoVo. Results showed that commercial anti-ADAM10 antibodies 
resulted to be effective in inhibiting cell migration and HER2 ECD release in LoVo cell line 
while IgG fraction purified from representative Crc patients did not. This lack of inhibition 
might be the consequence of the fact that LoVo cell line did not express the specific epitope 
that elicited the serological reactivity in Crc patients. In fact, Crc patients showed different 
expression of ADAM10 in tumoral tissues. Patients with a positive immunoreactivity 
against ADAM10 (Ser-ADAM10 +) showed an overexpression of the inactive form of 
ADAM10 and, accordingly, an high expression of the inactive HER2 (p195) isoform and a 
decreased expression of phosphorilated-ERK1/2. These results suggest a reduced activity of 
ADAM10 on the HER2 ECD cleaveage which is supported by the observation that Ser-
ADAM10 + patients showed lower HER2 ECD concentrations in serum compared to Ser-
ADAM10 - patients. 
 In conclusion, the presence of auto-antibodies anti-ADAM10 may be considered a 
biomarker of favourable prognosis for Crc patients at advanced stages of the disease that 
reflects an overexpression of inactive ADAM10 during the cell transformation and 
accordingly the lower protein maturation leads to a decrease of its sheddase activity which in 
turnt declines the proliferative and invasive capacity of tumor cells.  
Introduction 
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1. INTRODUCTION 
 
 
1.1. Etiology of Cancer. 
 
 According to the generally accepted monoclonal theory, cancer is a genetic disorder 
which originates from a single cell, after the addition of multiple mutations in certain genes 
that control cell behavior, which in turn promote invasion of other tissues and uncontrolled 
multiplication [1].  
  The genetic alterations that cause cancer may act on three different types of genes 
producing opposite effects [2]: 
1. Tumor suppresor Genes: genes whose function is to limit cell division and remove dead 
or damaged cells, such genes may be inactivated. 
2. Protooncogenes: genes whose function is to promote movement and proliferation in 
normal cells, these genes may be abnormally activated. Protooncogenes can be 
converted in oncogene due to a mutation and, subsequently, oncogenes are translated 
into oncoproteins with abnormal enhancement of activity.  
3. DNA repairing genes: genes that are involve in DNA repair and that may be inactivated. 
 The result is the inactivation of tumor suppresor genes or activation of oncogenes. 
The classical theory of carcinogenesis is summarized in three consecutive phases known as 
initation, promotion and progression (Figure 1). Initiation phase comprising the time in 
which carcinogenesis initiators such as UV light, ionization radiation, thermal disruption, or 
chemical sources induce an irreversible event in a single cell and the DNA damage remains 
unrepaired [3]. In the promotion phase , the damaged cell plays a tumor promoter role, they 
can be inducted to proliferate and undergo clonal expansion in which a generation of cells 
with mutated genes is formed. The progression of the tumor take place when further 
mutations, epigenetic changes or genetic instability confer to the cells a more aggressive 
capacity to invade distant places, leading to malignant tumour transformation. 
Introduction 
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Figure 1.  Monoclonal theory of carcinogenesis. [From 2] 
 
1.2. Colorectal cancer (Crc). 
 
 Colorectal cancer is one of the leading causes of lethality related to tumor 
pathologies in the United States, Crc is the third most common cancer both in men and 
women. Despite conventional treatments (surgery, chemoterapy, and radiotherapy) for 
Colorectal cancer which have improved in recent years, individuals with advanced disease 
still have a poor prognosis [4]. 
 The Crc survival rate is calculated according to the percentage of people who survive 
at least five years after the cancer diagnosis, excluding those individuals that die by other 
unrelated causes. 
 The five-years survival rate depends on the clinical development of the disease at the 
first hospitalization:  
• Is 90% in cancer in the early stage (in situ). 
• Is 70% in cancer cells are found  nearby lymph nodes or organs.  
• Is 13% when cancer cells are found in distant parts of the body.  
ISRN Oncology 3
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Figure 1: Classical theory of carcinogenesis. Cancer is generated by a three-step process: initiation, promotion, and progression. Several
mutations are needed to develop a cancer.
If DNA damage remains unrepaired, a promoter induces a
clonal expansion of the cell and a generation of cells with
mutated genes is formed in the so-called promotion phase.
Once a tumour is established, then mutation, genetic insta-
bility, or epigenetic changes can lead to new clones that con-
tribute to tumour expansion (clonal evolution model). It
should be noted that three types of genes can be altered to
yield cancer.
(1) Protooncogenes. These are normal genes that can become
oncogenes due to a mutation [11], which changes the
structure and function of a normal protein and generates an
oncoprotein. Comparing with the normal protein, oncopro-
teins can cause an increase in the protein activity, a loss in
regulation, or an increased concentration (due to an increase
of protein expression, of mRNA stability, or a chromosomal
abnormality). Examples of proto-oncogenes include RAS,
WNT,MYC, ERK, and TRK.
To distinguish between proto-oncogenes intrinsic in the
cell and those incorporated by viruses, oncogenes are named
as c-oncogenes (or cellular oncogenes) and v-oncogenes (or
viral oncogenes).
(2) Tumours Suppressor Genes. These genes protect the cell
on the path to cancer. Nevertheless, when a tumour suppres-
sor gene is mutated, the cell can progress to cancer. Although
the multiple-hit hypothesis [8] indicates that further muta-
tions have to be observed to progress to cancer, in some cases,
a mutation of a single allele can cause increased carcinogen
susceptibility [12]. Examples of tumours suppressor genes
include APC, TP53, SMAD4, SMAD2, and DCC.
(3) DNA Repairing Genes. Over 130 genes are thought to
be involved in DNA repair mechanisms in humans. DNA
repair mechanisms include single-strand DNA damage (base
excision repair (BER), nucleotide excision repair (NER),
mismatch repair (MMR)) and double-strand DNA damage
(nonhomologous end joining (NHEJ), microhomology-
mediated end joining (MMEJ), and homologous recombina-
tion (HR)) [13]. DNA repair defects can result in inactivation
of tumour suppressors or activation of oncogenes, causing
cancer. The main DNA repairing genes are MSH2, MSH3,
MSH6,MLH1, BLM, and PMS2.
The multihit hypothesis suggests that several successive
mutations in the same cell, probably about seven in the case
of human cancer, would be necessary to develop a cancer [8].
Obviously, it cannot be assumed that any seven mutations
will cause cancer. Only mutations which increase the ratio
between cellular divisions and cellular loss in a positive
direction in the environment may be expected to have this
effect.
1.2. Modern Aspects in Colorectal Cancer. In the last decade
of cancer studies, it has been observed that when normal
cells progressively evolve to a neoplastic state, they acquire
six biological capabilities during the multi-hit development
of tumours. In fact, tumours are more than insular masses
of proliferating cells, and they have often been compared to
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Nevertheless, surgical removal of the tumor supported by chemoterapy and radiotherapy 
treatments may improve the five-years survival rate for the patients. 
 
1.2.1. Colon and rectum: General description. 
 
 The last part of the digestive system is the large intestine which is consecutive to the 
small intestine (ileum) and, from there to the final is composed by cecum, ascending colon, 
transverse colon, descending colon, sigmoid colon, rectum and anus (Figure 2). 
 
 
Figure 2. Colon and rectum anatomy [From 5]. 
   
 The colon is the part of the large intestine with the function of absorbing water, salts 
and some vitamins from solid waste before they are discarded. Moreover the colon mantains 
the fluid balance and, with the aid of the gut flora, is able to ferment the undigested 
carbohydrates, favouring the subsequent absortion of these products by the cells of the 
intestinal lining. After the fermentation and absorption, the remaining waste products, 
named feces, reach the rectum and are discarded through the anus. 
 The colon has an inside space called lumen and histologically from the inner lining 
towards the outside is made up by several layers (Figure 3): 
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. The Mucosa, the innermost part of which is the glandular epithelium forming the villi 
which project into the intestinal tract and the characteristics crypts of Lieberku ̈hn that 
project into the deeper part of the mucosae; subsequentely there is the lamina propria 
containing reticular connective tissue and mucosal glands, and finally the muscularis 
mucosae that separates mucosa and submucosa.  
. The Submucosa, is composed by dense irregular connetive tissue that contain blood 
vessels, lymphatic vessels, nerve fibers and mucosal glands.  
. The Muscularis, composed by two consecutive layers of smooth muscle, gives to the 
intestine the ability to contract. The inner layer is circular while the outer layer is 
longitudinal. Between the two muscle layers there is the myenteric or Auerbach's plexus 
which controls the coordinated contractions of these layers.  
. The Serosa, is a smooth membrane which comprises two layers. The outer layer consists 
of secretory epithelial cells, and the inner layer consists of connective tissue. 
 
 
 
Figure 3. Schematic image representing the several layers of the colon [From 6]. 
Introduction 
11 
 
1.2.2. Colorectal cancer development: adenoma-carcinoma sequence. 
 
 There are several types of Crc, the adenocarcionoma is the most frequent with an 
incidence of 90-95% of all Colorectal cancers affecting the glandular epithelium, 
specifically the lining of colon and rectum. Cells develop an ordered series of events 
beginning with the transformation of normal colonic epithelium to an adenomatous 
intermediate and subsequently to an adenocarcinoma (Figure 4). 
 
Figure 4.  Progression of tumoral mass through the colon layers. The adenocarcinoma starts from the glandular 
epithelium where it forms polyps which can evolve in adenomas. The adenomas are polyps with different 
microscopic aspect that show an abnormal cell growth, and when are limitated to the mucosa, they are known 
as cancer-in situ. The polyps are kept in the area where they first developed and are not able to spread. When 
polyps became able to reach the submucosa, are considered adenocarcinomas and therefore malignant.  
 
 There is no particular cause that trigger the disease, except for the development of 
polyps. These projecting mass of overgrown tissue from the inner lining to the lumen would 
be a clonal expansion of the tumor promoter according with the Monoclonal theory of 
carcinogenesis [1] (Figure 1) and might develop in cancer as consequence of new mutation 
events that would contribute to tumor expansion. The polyps are considered benign unless 
an abnormal cell growth is detected microscopically; in this case the growing cells are 
Cancer;in'situ'
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defined adenoma and are limited to the inner layer being not able to spread beyond of the 
mucosa. The polyps and adenomas are also defined cancer-in-situ. When the tumor reaches 
the submucosa, it has the potential to spread and is defined as invasive adenocarcinoma, a 
malignant epithelial tumor that is capable of growth exceeding the different layers of the 
colon as its size increases dimensions.  
 When the primary tumor has gone through all strata, it may leave the epithelium and 
infiltrate nearby lymph nodes as well as it may reach other parts of the body giving rise to 
distant metastasis. 
 
1.2.3. Stages in Colorectal cancer. 
 
 Crc are classified according to their pathological stages, based on the size and 
invasiveness of the tumor. The most commonly used staging system of classification which 
is accepted by the American Joint Committee on Cancer (AJCC) and the Union for 
International Cancer Control (UICC) is based on Tumor/Nodes/Metastasis (TNM) score 
which define important pathological transition phases (Figure 5). 
 The three letters combined in AJCC system mean the following: T determines the 
size of the primary tumor; N informs about the lymph nodes infiltration both near and 
distant lymph nodes; while M defines the presence of metastasis and the possible formation 
of secondary tumors by spreading of primary tumor: 
* Primary Tumor (T). 
TX: Primary tumor cannot be evaluated. 
T0: No evidence of primary tumor. 
Tis: Carcinoma in situ (CIS; abnormal cells are present but have not spread to neighboring 
tissue; although is not a cancer, CIS may become cancer and is sometimes called preinvasive 
cancer). 
Introduction 
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T1, T2, T3, T4: Size and/or extent of the primary tumor. 
* Regional Lymph Nodes (N). 
NX: Regional lymph nodes cannot be evaluated. 
N0: No regional lymph node involvement. 
N1, N2, N3: Degree of regional lymph node involvement (number and location of lymph 
nodes). 
* Distant Metastasis (M). 
MX: Distant metastasis cannot be evaluated. 
M0: No distant metastasis. 
M1: Distant metastasis are present. 
 
 
Figure 5.  Tumor/Nodes/Metastasis (TNM) classification in Colon cancer (A) and schematic representation of 
different stages (B).  Depending on the mass tumor invasion of different layers of the colon, an internal 
stadium classification T that measure the extent of the primary tumor is assigned. The presence or absence of 
infiltrate lymph nodes is indicated by the designation N, while M reports signs of metastasis and spread to 
other organs [From 7]. 
 
(A)! (B)!
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1.3. Antibody-mediated response against Tumor Associated Antigens in 
cancer. 
 The immune system is able to distinguish between self and non-self antigens in order 
to protect our body against potentially damaging foreign organisms that may cause disease. 
The non-self proteins bear special tags that are recognized by our immune system triggering 
an adaptive response mediated by both T cell (cell mediated immune response) and B cell 
(antibodies immune response). On the contrary the self proteins do not carry any label and 
are ignored by the immune system with the exception of autoimmune diseases. It is well 
known that in cancer, the self-tolerance is broken in an effort to eliminate malignant cells 
and the immune system is activated in response to aberrant qualitative and quantitative 
expression by tumor cells of certain proteins named tumor-associated antigens (TAAs) [8, 
9]. 
 TAAs are classified into several categories on the basis of their expression 
characteristics [10]: 
Mutated — these are proteins with unique mutations in their amino acid sequence that are 
present only in cancer cells. 
Differentiation — expressed by a limited range of normal tissues.  
Overexpressed — these antigens can be expressed on a wide range of normal tissues, but are 
expressed at much more high levels in tumours. 
Idiotypic — unique protein sequences in the T cell receptor (TCR) or B cell receptor of 
leukaemias and lymphomas. 
Oncoviral — proteins encoded by tumorigenic viruses. 
 These aberrant tumor-associated proteins may confer an advantage to the tumor cells 
both in uncontrolled growth and invasion capability [2]. The humoral immune response is 
induced to produce auto-Abs anti-TAAs with the support of T-helper cells, with the aim to 
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recognize the aberrant proteins as foreign antigens. The presence in the serum of auto-Abs 
anti-TAAs reflects the occurrance of molecular events related to malignant transformation 
due to dysregulation of cellular mechanism. 
 At present, it is not known the mechanism by which the TAAs become 
immunogenic, however the recognition of self-proteins by the immune system may be 
leaded by changes in the TAAs structure, their aberrant regulation or their overexpression 
[11]. It has been reported that most of the target antigens are cellular proteins with possible 
functions in tumorigenesis pathways such as tumor-suppressor p53 [12, 13] or proteins 
involved in cell progression and invasion such as HER2/neu [14]. The modifications of these 
proteins might also alter their normal physiological function and the protein dysregulation 
could contribute to cancer development [2].  
  
1.4. Immunoproteomics. 
 
 Immunoproteomics is a methodological approach that exploit the presence of auto-
Abs in the sera of patients for the identification of antigenic proteins eliciting the humoral 
response in different pathologies such as autoimmune disease, infection and cancer [15, 16, 
17]. 
 The immunoroteomics approach exploit the fact that auto-Abs in the serum are stable 
with a long half-life and that the amplified humoral response make easier the detection also 
of antigens that are poorly expressed. 
 The immunoproteome-based approach is one of the methodologies largely used for 
the identification and characterization of new TAAs in cancer. Over the past decade, the 
proteomic techniques have experimented a technological development that has allowed to 
screen a large member of sera in order to improve the detection of many TAAs 
concomitantly [18, 19].  
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 Serological proteome analysis (SERPA) uses patient sera to screen proteins from 
primary tumor tissues or cell lines combining the separation of tumor proteins on two-
dimensional gel electrophresis (2DE), Western blot with patients and healthy subjects sera, 
image analysis and antigenic protein identification by mass spectrometry (MS) analysis 
(Figure 6). This approach allows the screening of a large number of patient sera and to 
establish the frequency of the reactivity against relevant auto-antigens [20]. The high 
throughput screening can be done on available tumor cell lines being reported that the 
serological reactivity on cell lines are comparable to that obtained on the autologous tumor 
proteome (Figure 7) [19]. In addition, SERPA enables to distinguish immunoreactivity 
toward protein isoforms and/or directed against post-translational modifications (PTM) 
(such as phosphorylation, glycosylation or protein cleavage), which is of central importance, 
being the protein immunogenicity frequently associated to unusual isoforms or to different 
PTMs occurring during tumoral transformation [19, 21]. 
 
Figure 6. Schematic representation of the workflow for tumor associated antigens identification by SERPA 
that exploits the presence of autoantibodies directed against tumoral proteins in the sera of patients. 
2D-Electrophoresis 
Tumor 
cell line 
Western-blot 
Proteins identification 
by mass spectrometry 
Image Analysis 
SERPA (Serological Proteome Analysis) 
patients sera 
controls sera 
Álvarez-Fernández et al. Fig. 1 
Spots excision from 
prepartive 2DE 
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Figure. 7 Proteome obtained from tumor cell lines is representative of the primary tumor proteome. Colon 
cancer patient serum reactivity on the autologous tumor proteome and on the proteome from three different 
Colon cancer cell lines (LS180, HT29 and LoVo) shows shared reactivities (underlined by circles). 
 
1.4.1. Immunoproteomics on Colorectal cancer. 
 
 In our laboratory, a SERPA on the proteome of the LS180 Colon carcinoma cell line 
has been performed using sera from Crc patients with the aim of identify news TAAs. A 
panel of six intracellular proteins eliciting a serological immune response in Crc patients has 
been identified [19]. However, none of these proteins specifically expressed or over-
expressed in tumor cells, that elicited an humoral response in Crc, were surface membrane 
expressed proteins. Since the surface membrane proteins could represent an ideal therapeutic 
target in cancer, in order to identify auto-Abs directed against putative TAAs in the surface 
membrane compartment, an enrichment procedure of this compartment was performed using 
surface protein biotinylation followed by affinity chromatography. The enriched material 
was coupled with SERPA performed using pool of sera from Crc patients and a pool of sera 
from healthy subjects. 
 This approach allowed the identification of some candidate proteins as TAAs, among 
these the membrane metalloprotease ADAM10 (A Disintegrin And Metalloprotease 10) 
[23]. ADAM10 is a cell surface metalloproteinasa that plays a potencial role in tumor 
progression and invasion [22].  The ADAM10 protein spot resolved by 2DE was specifically 
recognized by the pool of Crc patients sera, while the pool of Cn sera did not recognized it 
Patient serum reactivity on proteoma from:
autologous tumor LS180 HT29 Lovo
Álvarez-Fernández et al. Fig. 2 
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(Figure 8A). The same spot was reactive with the avidin-HRP as confirmation of its surface 
expression and was recognized by commercial antibody specific for ADAM10 (Figure 8A) 
confirming the mass spectrometry (MS) identification. The surface expression of ADAM10 
on LS180 cell line has been confirmed by immunofluorescence, being the reactivity of the 
anti-ADAM10 antibody present both in permeabilized and non-permeabilzed cells; the 
reactivity of the surface HLA class I molecule, and the reactivity against the intracellular 
protein β-actin, have been used as controls (Figure 8B). 
 
Table 1. Protein identification by MALDI-TOF MS analysis biotin-labelled spot [From 23]. 
 
 
Figure 8. (A) Serological Reactivity against ADAM10 enriched by cell surface biotinylation. Reactivity was 
obtained using a pool of Crc sera, a pool of Cn sera, avidin-HRP and commercial anti-ADAM10 antibody. (B) 
Immunofluorescence analysis on both permeabilized and non-permeabilized LS180 cells [From 23]. 
 
indicating that the protein is expressed on the cell surface. Similarly behave the 
reactivity of a well known surface marker as it is the HLA class I molecule. On the 
contrary, the reactivity against an intracellular protein like the actin, was visible only 
after cell permeabilization. 
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Fig.7 Confirmation of the cell surface expression of ADAM10 in LS180 cells. Anti ADAM10 
immunofluorescence reactivity is present at the surface of permeabilized and not permeabilized cells, 
as for the positive control HLA class I, whereas negative control, represented by the intracellular 
protein actin, is detected only on permeabilized cells 
 
 
4.5 Se ologic l screening on purified ADAM10 
Since a commercially purified form of ADAM10 was available we decided to perform 
a large screening on it by Western blot serological reactivity using a panel of sera 
from colon carcinoma patients. We tested 56 sera from colon carcinoma patients at 
different disease stages; in particular we used as patient stratification criteria the 
presence of tumoral cells in the lymphnodes surrounding the tumor because this is an 
important predictive value from the clinical point of view for the patients prognosis. 
The data set included 24 patients of stage I and II, in which the lymphonodes were not 
infiltrate by tumoral cells (indicated by TNM international classification as N0), and 
32 patients of stage III and IV, in which lymphnodes were infiltrated by cancer cells 
(indicated as Nx or M) (see Table 1 for the features). As control were used 39 sera 
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resulted to be also strongly biotinylated confirming membrane protein localization 
(Fig.5) 
 
Fig.5 Some serological reactivity of membrane proteins comparing Patient sera vs. Control sera,  
detection to ch ck their biotinylatio ,  corresponding spot on the 2-DE Coomassie blue stained gel and 
identity confirmation by specific antibody.  The data show stronger  patient sera reactivity than control 
sera reactivity and in most of the cases  Av-HRP confirmed the membrane protein localization. Specific 
commercial antibodies confirmed their mass spectrometry identification. 
 
4.3 Identification of membrane proteins 
With pattern matching analysis performed on gels and exposure film images, assisted 
by Progenesis software, we found the spots corresponding to serological reactivity, on 
preparative Coomassie blue gel of the same enriched material (Fig.6). 
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Table 2 
Protein identification by MALDI-TOF MS analysis 
         
Spot IPI 
Acc.No. 
Swissprot Entry name Protein name 
Seq. 
Cov. pI / Mr exp 
Mowse 
Score 
Meas. 
Pept. 
Matc. 
Pep. 
1 IPI00013897 O14672 ADA_10HUMAN ADAM 10 16% 5.59 / 66346 90 16 10 
          
IPI: International Protein Index; Acc. No.: Accession number; Seq. Cov.: sequence coverage; pI: isoelectric point; Mr: relative molecular mass; exp.: 
experimental; MOWSE: probability based score used by Mascot programme; Meas. Pep.: measured peptides; Matc. Pep.: matching peptides; WB: 
validation by Western blot 
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1.5. General description of ADAM10. 
 
 ADAM10, also named Kuzbanian, is a surface type I transmembrane glycoprotein of 
748 amino acids in length with a conserved domain organization [24]. From the extracellular 
to intracellular domain, ADAM10 is composed by a Prodomain (P), Metalloproteinase (M), 
a Disintegrin-like (D), a cystein-rich (Cys), a transmembrane (T) and a cytoplasmic (C) 
domains [25, 26, 27]. 
 The prodomain contains a signal peptide that permit an efficient transport of the 
protein to the membrane and contributes to the correct protein folding because acts as a 
molecular chaperone. In addition, the prodomain maintains ADAM10 in an inactive form 
preventing enzymatic activities when not required, in fact ADAM10 is a proteinase enzyme 
initially synthesized as inactive precursor protein of 98 kDa [28]. After synthesis and 
translocation in the endoplasmic reticulum ADAM10 is delivered and further processed to 
mature form in the Golgi compartment where the protein is subjected to glycosilation. Upon 
transit through the trans-Golgi network, the prodomain of ADAM10 is removed by 
endoproteolytic processing due to activation of proprotein convertases such us PC7 or Furin 
[28]. Generating and enzymatically active ADAM10 of 64 kDa, the mature enzyme is then 
transported to the plasma membrane, where it can act in shedding the ectodomain of several 
different membrane bound receptors, adhesion molecules, growth factors and cytokines like 
TNF-alpha [29, 30, 31, 32], Notch [33, 34], E-cadherin [35], Ephrin [36], HER-2 [37], 
CD30 [38] and CD44 [39] receptor. 
 The catalytic activity of ADAM10 resides in the metalloprotease domain which 
contains a zinc-binding motif implicated in the hydrolytic processing of substrate proteins. 
The prodomain has a single cysteine residue that interacts with the zinc atom in the catalytic 
domain forming an intramolecular binding complex that keeps the protein in an inactive 
state by an inhibitory mechanism called “the cysteine switch” [40]. Pro-protein convertases 
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 are able to remove the prodomain allowing the dissociation of the cysteine from the zinc 
binding site which in turn allows the exposure of the catalitic site leading the activation of 
the protein [28] (Figure 9).  
 
 
Figure 9. Schematic representation of the domains structure of ADAM10 and its activation by prodomain-
cleavage. 
  
 Shedding defines a process by which several cell surface proteins are cleaved in a 
site close to the membrane surface, resulting in the release of the extracellular domain. This 
process is commonly known as Proteolytic ectodomain release [41, 42]. ADAM10 belongs 
to the ADAMs family which is considered as the major family of mammalian surface 
membrane proteins with ectodomain sheddase activity [27] (Figure 10). 
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Figure 10. Schematic representation ADAM10-mediated shedding of transmembrane proteins which in turn 
leads to the release of soluble extracellular domains (ECD). 
 
1.6. Roles of ADAM10 for health and disease. 
 
 ADAM10 is especially prominent in epithelial tissues such as epidermis, kidney 
tubules and the endocardium and myocardium of the heart. Moreover, ADAM10 is present 
in mesenchymal cells which have a critical role in the epithelial-to-mesenchymal 
transformation [43]. In particular, the function of ADAM10 is physiologically involved in 
ectodomain shedding of several receptors (e.g., Notch, amyloid precursor protein) [44], 
adhesion molecules (e.g., N-cadherin, E-cadherin) [45], and ECM components (e.g., type-IV 
and type XVII collagen) [46, 47] that control many processes during the development, 
postnatal neurogenesis, tissue morphogenesis and homeostasis [33].  
 In a non pathological environment, cells are exposed to physiological replacement 
due to cellular repair and regeneration. Cell communication is fundamental to allow cell 
adhesion and migration whose are key processes to perform tissue regeneration. Cells 
interact with their microenvironment and respond to extracellular stimuli in order to keep 
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under control different processes such us differentiation, proliferation, migration and death. 
All these different signals are transmitted to the cell through intracellular pathways and the 
cell has to respond based on them. Hence, any aberrant modification of these signaling 
pathways could contribute to the development of cancer. Moreover, cell migration is 
necessary to the tissue remodelling but also drives tumor metastasis during malignant 
transformation so it is critical for tumor cells traveling to distant sites [60]. 
 Sheddase activity confers to ADAM10 the ability to influence cell adhesion and cell-
cell interactions inducing the remodeling of the extracellular matrix (ECM) [61] and the 
ability to regulates the activation of growth-stimulating factors because is involved in their 
ectodomain-shedding promoting cell proliferation and cell survival. In particular, it has been 
reported that ADAM10 is the major metalloproteinase able to activate the specific cell 
surface receptor HER2 by shedding its ECD in breast cancer cells [37]. Since activation of 
HER2 participate in the regulation of important cellular functions, the ADAM10-mediated 
cleavage fosters cell differetiation and proliferation allowing migration and cell survival. 
The dysregulation of the ADAM10 functions may result in further pathological 
processes including inflammation and cancer progression [49]. Indeed, the loss of the cell 
adhesion molecule E-cadherin was shown to promote invasiveness of tumors [50, 51]. Cell 
dissociation is key step to induce cell migration, invasion and consequently to promote 
metastasis. Interestingly, a large number of publications showed the overexpression of 
ADAM10 in variety of tumors: neuroblastoma, pheochromocytoma [52], hematological 
malignancies [53], androgen-dependent prostate cancer [55], oral squamous cell carcinoma 
[56], neoplastic gastric mucosa [57], uterine and ovarian carcinomas [58], and colorectal 
cancer [59]. In the latest, high expression of ADAM10 correlates with advanced stage of the 
disease [22] suggesting that this protein play an important role in tumor progression and 
invasion.   
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  Aberrant qualitative or quantitative expression of ADAM10 by tumor cells might 
confer an advantage on tumor dissemination. Hence, the role of ADAM10 in cancer 
development seems to be crucial. 
 
1.6.1. Sheddase activity on Epidermal growth factor receptor 2 (HER2). 
 
 The Epidermal Growth Factor Receptor (EGFR) family is made up by four receptor 
tyrosine kinases (RTK): EGFR/HER1/erbB1, HER2/erbB2, HER3/erbB3 and HER4/erbB4. 
HER1, HER3 and HER4 bind a soluble ligand (e.g., EGF, betacellulin, amphiregulin) 
allowing to change its conformation from close to open. The open conformation promotes 
the receptor dimerization between family members. The heterodimer formation is 
fundamental for the receptor activation by phosphorylation and activation of the intracellular 
tirosine kinase domain located at the C-terminus.  
 On the contrary of HER1-3, HER2 as full-length (p195) does not bind any ligand as 
it is constitutively in open conformation and, maybe for that reason is the preferred partner 
for heterodimer formation. HER2 contains an extracellular domain (divided in 4 sub-
domains), a transmembrane domain, and an intracellular domain. While the intracellular 
domain is responsible for phosphorylation and nessesary for the signaling trasmission, the 
extracellular domain is the portion of the molecule where the signal transduction starts. 
Indeed, HER2 is activated by cleveage of its extracellular domain (ECD; p100), which is 
released in the extracellular space, and the truncated form (p95), which remains in the 
membrane shows an increased phosphorylation of the intracellular tyrosine kinase activity 
[63] resulting both in increased autophosphorylation and increased phosphorylation of 
targets molecules. 
 These phosphorylated residues are recognized by different downstream mediators of 
signal transduction that regulate several genes that affect some cellular processes such as 
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proliferation, migration, and cell survival [64, 65]. In particular, oncogenic signaling by 
HER2 involve the activation of MAPK-ERK pathway which contributes to enhanced cell 
division [66] (Figure 11). Thus, HER2 activation plays an important role in tumor 
invasiveness and metastasis formation.  
 Interestingly, ADAM10 is the major protease responsible for HER2 ectodomain 
sheddase activity [37] which in turn promotes HER2 activation and, accordingly, tumor 
progression. 
 
 
 
Figure 11. ADAM10 activates the HER2 tyrosine kinase receptor by ectodomain cleavage which trigger the 
activation of downtsream signaling pathway promoting cell division and cell survival. 
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2. AIM OF THE THESIS 
 
 
  In a previous work, ADAM10 had been identified as putative TAA eliciting a 
serological immune response in Crc patients. Therefore, the first aim of this project was to 
confirm in a larger cohort of Crc patients the presence of auto-Abs against ADAM10 and 
substantiate the immunogenicity of ADAM10 as TAA. In particular, we would like to 
investigate whether the immunoreactivity against ADAM10 correlates with the disease 
stages and progression.  
  Since ADAM10 plays an important physiological role in epithelial morphogenesis, 
with the aim to understand whether the immunoreactivity against a specific TAA is a feature 
of a specific type of tumor or is a characteristic that can be shared with others tumors, we 
investigated the presence of the anti-ADAM10 immunoreactivity in sera from tumors with 
epithelial and non-epithelial origin. 
  Finally, TAAs are used as early detection markers for malignant transformation, but 
little is known about the effects that the presence of anti-TAA auto-Abs might have on the 
progression of the disease. Thus, a further scope of this work was to understand whether the 
presence of these auto-Abs anti-ADAM10 might affect the Crc progression, either in 
favourable or detrimental way, and based on the results to investigate the possible effects of 
the auto-Abs on the physiological activity of the ADAM10. 
Results 
26 
 
3. RESULTS 
 
 
3.1. Colorectal cancer serological screening on purified ADAM10. 
 
 With the aim to investigate ADAM10 as TAA candidate in Crc, a serological 
screening on purified recombinant ADAM10 (rhADAM10) resolved by SDS-PAGE was 
performed by Western blot. Sera from Crc patients and healthy subjects were used to test the 
presence of auto-Abs specific for ADAM10 as immune response elicited by the protein 
(Figure 12).  
 
 
 
Figure 12. (A) Ponceau red staining obtained loading 200ng of rhADAM10 in each line. (B) Some examples 
of immunoreactivity obtained in the serological screening on purified rhADAM10. Control sera 70, 60, 29, 1, 2 
immunoreactivity; Crc patient sera 36, 19, 27, 37, 72 immunoreactivity. 
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 All signals were normalized according to the reactivity obtained with a commercial 
anti-ADAM10 antibody (R&D systems) used in all experiments. The normalized optical 
density (OD) was directly proportional to the intensity of immunorectivity against ADAM10 
and therefore representative of the presence of auto-Abs. 
 Sera from 106 Crc patients were analyzed. This Crc cohort included 52 patients of 
stage I-II, in which the lymphonodes were not infiltrate by tumoral cells (indicated by TNM 
international classification as No), and 54 patients of stage III-IV, in which lymphnodes 
were infiltrated by cancer cells (indicated as N or M) (Table 2). This patient stratification is 
an important predictive value from the clinical point of view for the patient prognosis. As 
control cohort (Cn) were used 91 sera from healthy subjects or subjects with pathologies 
not-correlated with tumoral transformation, in order to exclude non tumor-specific 
immunoreactivity of these autoantibodies, like for example as induced by inflammatory 
status. Age and gender distribution between patients and controls groups resulted to be 
homogeneous with exception of comparison with breast carcinoma population (Table 2). 
 The analysis of normalized OD (OD values for each serum are reported in Appendix) 
showed that the immunoreactivity against ADAM10 was higher in patient sera compared to 
control sera (Cn vs. Crc, p<0,0001, Mann-Whitney test) (Table 2 and Figure 13A). The 
significant difference was maintained comparing controls with either patients at early 
disease stages (I-II) (Cn vs. CrcN0, p=0,0004), and patients at late disease stages (III-IV) (Cn 
vs. CrcN, p<0,0001). Relevant differences were also found when the three independent 
groups were evaluated together by covariance Kruskal-Wallis test (p<0,0001) (Figure 13A), 
with post analysis test significant for Crc vs. Cn (p< 0,001) and CrcN vs. Cn (p< 0,001) 
comparisons. 
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Table 2. Serological reactivity for ADAM10 using 237.2 OD as cut-off value. 
 
 
 
Figure 13. Analysis of the serological immunoreactivity against ADAM10 measured as Western blot signal 
optical density (OD). (A) Statistical analysis performed by Mann-Whitney (M-W) and Kruskal Wallis showed 
that Crc sera reactivity vs. Cn sera was extremely statistically significant on both Cn vs. Crc-N (patients at late 
stages III-IV) and Cn vs. Crc-No (patients at early stages I-II). (B) Receiver operating characteristic (ROC) 
analysis. Increasing sensitivity and specificity values from 0 to 1 determined for the serological screening an 
area under the curve (AUC) value of 0.7124 with p<0.0001 statistical significant, indicating that the serological 
screening on ADAM10 have a powerful discriminative capacity between the tumoral patients and control 
groups (**** = p<0,0001; *** = p<0,001; ** = p<0,01; * = p<0,05). 
  
 The ROC analysis of Cn vs. Crc anti-ADAM 10 reactivity, indicated an area under 
the curve (AUC) of 0.7124 with a p value <0.0001 (Figure 13B), which in turn suggested 
that the test may have a discriminating capacity between the two groups. ROC analysis was 
performed in order to choose the value with the best balance between sensitivity and 
specificity, indicating to the OD threshold value of 237.2 as discriminat in order to define 
the reactivity as positive (+) or negative (-). This value roughly coincide with the OD mean 
Stage I-II Stage III-IV
n (m/f) Age normalized OD 237.2 OD cut-off n (m/f) normalized OD 237.2 OD cut-off n (m/f) normalized OD 237.2 OD cut-off
Crc 106 (58/48) 67.1 sd 11.6 595.8 se 56.9 78+ 28- 52 (27/25) 560.6 se 77.47 36+ 16- 54 (31/23) 629.7 se 83.57 42+ 12-
Cn 91 (37/54) 63.8 sd 14.41 261.7 se 22.26 34+ 57- - - - - - -
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value of control sera (261.7 se 22.26) and gave rise the better sensitivity of 0.74 and 
specificity of 0.63. The relevance of the use of this threshold value was confirmed by the 
Fisher’s test analysis that indicated a significant discrimination between Cn and Crc patients 
(p<0.0001). When the patients were considered in two groups based on the infiltration of the 
lymph nodes, the Fisher’s test showed higher difference in patients at later stages (III-IV) 
(p<0.0001) if compare with the group of patients at early stages (I-II) (p=0.0003). 
Sensitivity and specificity of this putative marker were confirmed for the cancer cohort in 
toto and, ss expected, the sensitivity and specificity increased if only patients at advanced 
stages were taken into consideration (Table 3). 
 
Table 3. Fischer’s test 
 
 
 Taken together these results suggest that the serological reactivity against purified 
ADAM10, found in Crc patients sera can be proposed as a putative pathological marker. 
Neg
Crc 28
Cn 57
CrcN0 16
CrcN 12
sens. spec.
0.74 0.63
0.74 0.63
0.78 0.64
sens= sesitivity; spec= specificity
OD= optical density; Cn= control sera; Crc= colon cancer sera; ,
N0= no tumor cells infiltrating lymphnodes; 
N= tumor cells infiltrating lymphnodes 
Fischer's test
Crc vs  Cn p<0,0001
CrcN0 vs  Cn p=0.0003
CrcN vs  Cn p<0,0001
36 n= 52
42 n= 54
78 n= 106
34 n= 91
Serological reactivity for ADAM10
using 237.2 OD as cut-off value
Pos
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3.2. Serological screening of the immunoreactivity against ADAM10 in 
cohorts of patients with tumours of epithelial and non-epithelial origins. 
 Since ADAM10 expression suggests a physiological function in the morphogenesis 
of several epithelial tissues, with the purpose to investigate whether the serological reactivity 
against ADAM10 is a feature related to the epithelial origin of the tumor tissue, cohorts 
from tumours of both epithelial and non-epithelial origin were tested. As tumor of epithelial 
origin, in addition to Crc, were tested sera from Pancreatic cancer (Pc) (n= 43) and Breast 
cancer (Bcr) (n=35) patients, while as malignant transformation of non-epithelial origin 
were tested sera from patients with hematological malignances such as B-cell chronic 
lymphocytic leukemia (B-CLL) (n=53) and Multiple Myeloma (MM) (n=46) (Table 4) (OD 
values for each serum are reported in Appendix). 
 
Table 4. Summary of the demographic and clinical features, and the anti-ADAM10 serological reactivity of 
the analyzed populations. 
 
 
 All sera were screened and normalized as for Crc sera. The frequencies of sera 
considered positive for the presence of antibodies against ADAM10 was significantly high 
both in Pc and in Brc compared with control sera (p=0.0006 and p=0.0027, respectively; 
Mann-Whiteney test) (Figure 14). On the contrary, there were no differences between sera 
from both patients of B-CLL and Multiple Myeloma vs. control subjects suggesting that the 
reactivity against ADAM10 was specific for tumors of epithelial origin. 
Stage I-II Stage III-IV
n (m/f) Age normalized OD 237.2 OD cut-off n (m/f) normalized OD 237.2 OD cut-off n (m/f) normalized OD 237.2 OD cut-off
Crc 106 (58/48) 67.1 sd 11.6 595.8 se 56.9 78+ 28- 52 (27/25) 560.6 se 77.47 36+ 16- 54 (31/23) 629.7 se 83.57 42+ 12-
Cn 91 (37/54) 63.8 sd 14.41 261.7 se 22.26 34+ 57- - - - - - -
Pc 43 (20/19) 66.77 sd 9.75 908 se 256.6 31+ 12- - - - - - -
Brc 35 (0/35) 51.51 sd 11.09 424.6 se 45.58 24+ 11- - - - - - -
B-CLL 53 (34/19) 65.55 sd 11.15 318.7 se 35.11 28+ 25- - - - - - -
MM 46 (21/25) 66.33 sd 10.48 298.4 se 49.21 22+ 24- - - - - - -
 anti-ADAM 10 reactivity  anti-ADAM 10 reactivity  anti-ADAM 10 reactivity
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Figure 14. Analysis of the serological reactivity against ADAM10 measured as Western blot signal optical 
density (OD). Statistical analysis performed by Mann-Whitney (M-W) on sera from patients affected by 
epithelial tumors vs. Cn sera showed a significant presence of auto-Abs against ADAM10, both Bc vs. Cn and 
Pc vs. Cn. On the contrary, no differences were found on immunoreactivity against ADAM10 in patients 
affected by non-epithelial tumors vs. Control, either BCLL vs. Cn or MM vs. Cn (*** = p<0,0001; *** = 
p<0,001; ** = p<0,01; * = p<0,05) (Cn=control subjects; Bcr=Breast cancer; Pc=Pancreatic cancer; BCLL= B-
cell chronic lymphocytic leukemia; MM=Multiple Myeloma). 
 
3.3. Follow-up analysis for disease free-condition in Crc patients. 
 
 In order to see whether the presence of auto-Abs against ADAM10 was a favourable 
or detrimental condition for the disease progression, we analyzed for disease-free condition 
(no tumor relapse and no metastasis) the follow-up of Crc patients from the time of surgical 
resection up to 73 months. We obtained information from n=96 Crc patients that were 
considered as two separated groups depending on the stage of the disease (early: stage I-II; 
late: stage III-IV) because in patients at early stage the possibility to record an event (tumor 
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relapse or metastasis or patient death) is very rare. For Kaplan-Meier survival curve and 
Log-rank test analysis we compared the patients showing immunoreactivity against 
ADAM10 vs. the patients with no reactivity, according to the serological analysis.  
 The follow-up analysis of Crc patients with disease at late stages (n=49) indicated 
that the presence of anti-ADAM10 auto-Abs in patients prolongs significantly the disease-
free condition (p=0.0034, Log-rank, test), about 14 months vs. 1 month at 50% of the 
population (Figure 15A). On the contrary, the follow-up analysis taking to account only the 
Crc patients at stages I-II (n=47) did not show enough events to be able to differentiate 
between Crc patients with positive and negative immunoreactivity against ADAM10 
(Figure 15A). 
 Therefore the presence of auto-Abs anti-ADAM10 may be considered a favourable 
prognostic marker in Crc patients with infiltrated lymph nodes (stages III-IV). 
 
 
 
Figure 15. Kaplan-Meier analysis of disease-free condition after surgery resection in patients at stage III-IV 
(A) and patients at stage I-II (B), according with the presence (ADAM10 pos) or not (ADAM10 neg) of 
immunoreactivity against ADAM10. The considered outcome was disease free, and the marked “event” was 
tumor relapse, metastasis and/or patient’s death.  
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3.4. Evaluation of the HER2 extracellular domain released in Crc patient 
sera.  
 The metalloprotease ADAM10 is the main responsible for the extracellular domain 
(ECD)-shedding of the HER2 receptor, and the released ECD from the cell surface can be 
detected in the serum. We quantified by ELISA the HER2 ECD concentration in both Crc 
and Cn sera. As expected, regardless the presence of anti-ADAM10 antibodies, Crc patients 
showed a significant (p<0.0001, Mann-Whitney test) higher amount of soluble HER2 ECD 
in the sera if compared to control subjects (Figure 16A). This is consistent with an increase 
of cell division in a tumoral behavior. In addition, a significant (p=0.0023, Spearman r 
correlation) reverse correlation (r= - 0.3) between HER2 ECD released in the sera and the 
OD reactivity for auto-Abs against ADAM10 was observed (Figure 16B). Crc patients with 
a positive presence of anti-ADAM10 auto-Abs showed lower HER2 ECD concentrations in 
serum that might suggest an ADAM10-mediated inhibition of HER2 ECD shedding.  
 
 
 
Figure 16. Evaluation by ELISA of HER2 ECD occurring in patient sera. (A) High HER2 ECD concentration 
was detected in the sera from Crc patients compare to Cn. (B) A reverse correlation between HER2 ECD 
concentration and the presence of auto-Abs against ADAM10 observed in Crc sera. 
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3.5. In vitro HER2 ECD release is inhibited by commercial anti-ADAM10 
antibodies.  
 To confirm a possible role of auto-Abs anti-ADAM10 in inhibiting sheddase 
activity, the release of HER2 ECD, due to ADAM10 activity, was evaluated in LoVo 
metastatic colon carcinoma cell line. As shown in Figure 17B, LoVo cells express both pro-
form and mature form of ADAM10 (98 kDa and 64 kDa respectively) as well as the HER2 
in a full-length (p195) and truncated form (p95). LoVo cells also present a constitutively 
activated ERK1/2 signaling as reported the expression of phosphorylated ERK1/2. LoVo 
protein expression indicated that a large fraction of ADAM10 is constitutively activated 
being present as mature form, and that HER2 is also constitutively cleaved since the 
truncated form is present and the ERK1/2 signaling is activated as read-out of HER2 
activation (Figure 17A). Therefore, the constitutively activated cleavage of HER2 ECD and 
the presence of active ADAM10 make this cellular model susceptible to inhibition by anti-
ADAM10 antibody treatment. Results indicated that the HER2 ECD shedding mediated by 
ADAM10 was inhibited by the presence of anti-ADAM10 antibodies. Cells tested with 
increasing concentrations of two commercial goat anti-ADAM10 antibodies separately, 
resulted in a dose-dependent decrease of soluble HER2 ECD concentration detectable in 
culture medium (Figure 17B). Control treatment with goat Immunoglobulin G (IgG) did not 
affect the HER2 ECD release.  
 Nevertheless, the Abs-treatment able to inhibit HER2 ECD release did not 
significantly affected LoVo cell proliferation nor seemed to affect the intracellular signaling 
pathway as assessed by ERK1/2 phosphorylation (data not shown). 
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Figure 17. (A) Protein expression in the metastatic Crc LoVo cell line. (B) LoVo cell line was treated for 72 
hours with increasing concentrations (25 μg/ml, 50 μg/ml, 75 μg/ml and 100 μg/ml) of two commercial goat 
anti-ADAM10 antibodies (US Biological and R&D systems) or IgG purified from goat serum (100 μg/ml) as 
control. Culture supernatants were collected and assayed by ELISA for the presence of soluble HER2 ECD.  
 
3.6. Commercial Anti-ADAM10 antibody blocked the migration of LoVo 
cell line. 
 Epithelial cell migration was analyzed in absence or presence of commercial anti-
ADAM10 antibody by wound healing migration test. The LoVo Crc cell line expressing 
ADAM10 was incubated with commercial goat anti-ADAM10 Ab (10 μg/ml). After 72 
hours LoVo cells showed a marked inhibition of the wound closure if compare with the cells 
incubated with IgG purified from goat (10 μg/ml) tested as control (T-test p<0.0045) 
(Figure 18). These results suggested that the possible interference of antibodies anti 
ADAM10 with ADAM10 functions results in a reduction of migratory properties of the 
tumoral cells. 
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Figure 18. Wound healing cell migration assay. (A) A representative experiment showed the inhibitory effect 
of the commercial goat anti-ADAM10 Ab (US Biological; 10 μg/ml) on LoVo cells migration. (B) After 72 hr. 
the presence of anti-ADAM10 Ab inhibited more than 50% of the wound closure. 
 
3.7.  In vitro effects of IgG purified from Crc patients sera on migration 
and HER2 ECD release. 
 The sera IgG fraction from representative Crc patients (6 positive and 6 negative for 
anti-ADAM10 serological reactivity) were purified on G-agarose and, subsequently, tested 
for purity in SDS-PAGE. The ponceau staining showed the presence of both light (25 kDa) 
and heavy (50 kDa) chains of the IgGs (Figure 19).  
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Figure 19.  IgG purified from Crc patients sera. Five μl of purified IgG from Crc patients with positive (Ser-
ADAM10 +) (C37, C20, C42, C36, C14, C19) and negative (Ser-ADAM10 -) (C52, C6, C50, C27, C45, C3) 
anti-ADAM10 serological reactivity were resolved by SDS-PAGE. Ponceau red staining showed both heavy 
(50 kDa) and light (25 kDa) chains of the IgGs. 
 
 In order to be sure that the purified IgGs retained the specific reactivity, they were 
tested for reactivity against purified rhADAM10, the results confirmed that the purified IgG 
preserved the immunoreactivity against rhADAM10 tested in the Crc serological screening 
(Figure 20). 
 
 
 
Figure 20. Representative immunoreactivity of the IgGs purified from Crc patient sera on rhADAM10 (in 
duplicate), showing the retention of the specific serologic reactivity as recorded before IgGs purification. 
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 The purified IgGs from Crc patients sera were used to evaluate whether, similarly to 
the commercial anti-ADAM10 Abs, might affect the functions of LoVo cell line expressing 
ADAM10. Wound healing test and HER2 ECD release assay were carried out. 
 Wound healing experiment was performed to test the effect of the purified IgGs on 
cell migration. After 72 hours of treatment, cell incubated with IgGs (10 μg/ml) from both 
Ser-ADAM10 + patients and Ser-ADAM10 – patients did not show significant differences 
in cell migration neither between them nor if compared with the cells incubated with 
medium alone (Figure 21A).  
 HER2 ECD release assay was performed in order to evaluate the effects of the 
purified IgGs on the ADAM10-sheddase activity. LoVo cells were incubated for 72 hours 
with IgGs (100 μg/ml) from both Ser-ADAM10 + patients and Ser-ADAM10 – patients. 
Soluble HER2 ECD released in the medium was measured by ELISA, and the results 
showed a concentration of HER2 ECD barely lower in cells treated with IgGs from patients 
compared to cells incubate with medium alone, which suggested a weak inhibition of the 
ECD release. However, IgGs purified from patients ADAM10 + did not inhibit in a 
significative manner the ECD release if compare with the cells treated with IgGs from 
patients ADAM10 – (Figure 21B). 
 In conclusion, the IgGs from Ser-ADAM10 + patients resulted not to be effective in 
inhibiting both tumoral cell migration and ADAM10 sheddase activity. 
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Figure 21. LoVo cell line incubated with IgGs purified from Crc patients sera with a positive (Ser-ADAM10 
+) or negative (Ser-ADAM10 -) immunoreactivity against ADAM10. (A) Wound healing experiment showed 
no significant inhibition of cell migration; results were calculated as the percentage of closed wound area 
referred to the initial total area of the wound (B) Evaluation by ELISA of HER2 ECD released in the culture 
medium. No significant differences in HER2 ECD release were observed between cells treated with IgGs 
purified from Ser-ADAM10 + patients compared to cell treated with IgGs purified from Ser-ADAM10 – 
patients; HER2 ECD levels are expressed as percent of inhibition referred to control cells treated with medium 
alone. 
 
 
3.8. Expression of ADAM10 and proteins targets of its sheddase activity in 
primary tumor tissues from Colorectal cancer patients. 
 With the aim of to evaluate the presence of different isoforms of ADAM10 in Crc 
primary tumor tissues, namely the mature active isoform of about 98 kDa and the inactive 
pro-protein of about 64 kDa, Western blot analysis was carried out on tumoral tissues from 
seven Crc patients. The samples include five patients with positive immunoreactivity against 
ADAM10 and two with showed no auto-Abs anti-ADAM10. The precursor (uncleaved) and 
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mature (cleaved) isoforms of ADAM10 were differentially expressed in Ser-ADAM10 + 
patients compared to Ser-ADAM10 - patients.  
 The tumors from Ser-ADAM10 + patients showed the expression of equal amount of 
mature and the immature pro-form of ADAM10, while the Ser-ADAM10 – patients showed 
a prevalent expression of the active mature ADAM10 (Figure 18). Then, we tested the 
expression of the HER2 receptor, the target of the ADAM10 sheddase activity, and the 
activation status of ERK1/2, a molecule downstream to the HER2 activation pathway, since 
it correlates with HER2 activation. 
    
 
 
Figure 18. Western blot analysis on colon specimens from Crc patients (patients with a positive 
immunoreactivity against ADAM10: C27, C38, C9, C21, C36; patients without immunoreactivity against 
ADAM10: C43, C52) for the expression of ADAM10 and its related proteins HER2, Total ERK1/2 and 
phosphorylated-ERK1/2. Reactivity with anti-β-actin mAb was used as a protein-loading control. 
 
 Accordingly to the predominant expression of the active ADAM10 mature form, the 
Ser-ADAM10 – patients showed faint or no expression of the HER2 (p195) isoform, 
Pro-form!
Mature!
HER2 (p195)!
Total ERK 1\2 !
P-ERK1\2 !
Actin!
C2
7!
C3
8!
C9
!
C2
1!
C3
6!
C4
3!
C5
2!
Ser-ADAM10 +!
ADAM10!
Ser-ADAM10 -!
75 kDa!
195 kDa!
43 kDa!
43 kDa!
42 kDa!
Results 
41 
 
possibly due to an increased HER2 ECD cleavage, that was confirmed by the activation of 
ERK1/2 signaling as indicated by strong ERK1/2 phosphorylation (Figure 18). On the 
contrary, Ser-ADAM10 + patients showing increased expression of immature ADAM10 
(inactive protein) reported an higher expression of the inactive HER2 (p195) isoform and a 
decreased expression of phosphorylated-ERK1/2, suggesting a lower activity of ADAM10 
on e HER2 ECD cleavage. 
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4. DISCUSSION 
 
 
 In cancer, TAAs are used in diagnosis as early detection biomarkers reporting in 
advance that malignancy transformation has been started in the organism and the immune 
system produce auto-Abs against these TAAs in an effort to counteract the tumor [8]. In the 
case of Crc, the presence of polyp or adenoma reports the beginning of abnormal cell growth 
and even if they are not able to spread beyond of the mucosa yet, they are able to elicit an 
immune response. In particular, in a previous work in the laboratory, with the aim to identify 
proteins eliciting humoral response in Crc patients, the membrane metalloprotease 
ADAM10 was identified as a putative TAA by a proteome-based approach (SERPA).  
 In the present study, ADAM10 was validated as TAA in a large number of Crc sera 
and control sera confirming the presence of a significant immunoreactivity anti-ADAM10 in 
Crc patients compared to healthy subjects. Moreover, in order to investigate whether anti-
ADAM10 serological reactivity is a specific feature of Crc or is a characteristic shared with 
others tumors, we found that also Pc and Brc, which are tumor of epithelial origin, elicited a 
significant anti-ADAM10 immunoreactivity, while sera from patients affected by 
hematological malignancies did not. This is consistent with the fact that ADAM10 play a 
critical physiological function in the epithelial cell development [43]. ADAM10 regulates 
several morphogenetic movements during embryogenesis such as cell proliferation, 
differentiation and remodeling of the extracellular matrix (ECM), vascularization and cell 
migration [43, 72]. These events occur several times during organogenesis in both normal 
development and during tumor progression [72]. Since the presence of ADAM10 is 
indispensable in the epithelial morphogenesis, any aberrant modification of the protein 
might elicit the immunorreactivity against ADAM10. Therefore, the presence of auto-Abs 
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against ADAM10 in patients sera might be a biomarker candidate for carcinomas of 
epithelial origin.  
 In particular, the disease course of the Crc patients with advanced stages, when the 
lymph nodes were infiltrated by the tumor cells, showed that the presence of auto-Abs anti-
ADAM10 prolonged significantly the disease-free condition. This was not occurring for Crc 
patients at early stages suggesting that the infiltrated lymph nodes is a critical point of the 
disease where the humoral response might confer an advantage in limiting the progression of 
the tumor. In fact, ADAM10 has been reported to be overexpressed in the advanced stages 
of the Crc [22], therefore it seems that is in these stages that the auto-Abs may have a crucial 
role in affecting tumor growth.  
 Since a favourable condition of the Crc patients with positive immunoreactivity 
against ADAM10 was observed, we hypothesized that the auto-Abs might recognized some 
specific part of the protein and inhibit its activity. Thereby, we focused on the possible 
effects that the auto-Abs anti-ADAM10 might have in Crc patients and on the possible 
correlation between the presence of high immunoreactivity and progression of the disease. 
The major activity of ADAM10 is known to be located at the metalloprotease domain that 
promotes the shedding of several membrane bound receptors [27], in particular ADAM10 is 
the major metalloprotease responsible for the ECD-cleavage of the HER2 receptor [37], 
which in turn became activated leading to cell proliferation [66]. The presence of HER2 
ECD released in serum is used as marker for Breast cancer metastases [73, 74] that indicate 
a poor prognosis. Therefore the observation that Ser-ADAM10 + patients showed lower 
concentrations of HER2 ECD in serum suggests that the auto-Abs anti-ADAM10 might 
inhibit in vivo the sheddase activity of ADAM10 in Crc patients. This hypothesis was 
confirmed in vitro when LoVo Crc cell line treated with two commercial anti-ADAM10 
antibodies showed a dose-dependent reduction of the amount of HER2 ECD released in the 
Discussion 
44 
 
culture medium. Therefore, consistently with the physiological function of the HER2 
receptor, the inhibition of the HER2 cleavage should promote also an inhibition of cell 
division [66], but we did not observe any decrease of either cell proliferation or 
phosphorylation of ERK1/2 (as read-out of reduced cell activation [66]). A possible 
explanation is that LoVo is a cell line with a constitutively activated ERK1/2 signaling 
(Figure 17A), thus the inhibition of the HER2 activation was not able to inhibit also, at least 
in vitro, the activation signaling which was already started. 
 ADAM10 is also able to influence cell adhesion and cell-cell interactions inducing 
the remodeling of the extracellular matrix (ECM) [61]. In vitro migration experiment using 
LoVo Crc cell line treated with commercial anti-ADAM10 antibody resulted to be effective 
in inhibiting cell migration. This might be of relevance since cell migration drives tumor 
metastasis during malignant transformation [60] and its inhibition might slow down the 
progression of the disease explaining the favorable prognosis of Ser-ADAM10 + patients. 
 These experiments indicated that the inhibition of ADAM10 results in a decrease of 
its sheddase activity in vitro. Therefore, in vivo, the decreased sheddase activity that occurs 
in patients might be due to a blocking effect on ADAM10 by the auto-Abs. In alternative, a 
possible explanation is that the detected immunoreactivity is a read-out signal elicited by 
aberrant modifications of the ADAM10 protein, and that such modifications make 
ADAM10 non-functional in the absence of any role for the auto-Abs. Thus, in order to 
evaluate in vitro the effects of the auto-Abs against ADAM10, IgG fractions were purified 
from sera of representative Crc patients and were used both on HER2 ECD-shedding assay 
and on wound healing experiment.  The aim was to differentiate between the effects of 
purified IgGs from Ser-ADAM10 + and Ser-ADAM10 – patients. We were expecting a 
significant high inhibition by purified IgGs from Ser-ADAM10 +, however, despite the 
successful IgG purification from the sera and the fact that they retained the specific 
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immunoreactivity against ADAM10, these Abs resulted not to be effective in inhibiting 
LoVo cell migration. In the case of HER2 ECD release assay, the purified IgG showed a 
pattern of inhibition which, however, did not correlate with Ser-ADAM10 + patients and 
probably was due to a non-specific effect of the Abs.  These results might be explained 
owing to the low amount of Ig fraction specific for ADAM10 present in the total amount of 
purified IgG. An alternative explanation is that the auto-Abs anti-ADAM10 were not 
effective because LoVo cell line did not express the specific epitope that elicited the 
serological reactivity in Crc patients. The recognition of tumor-specific epitopes presented 
in the anomalous protein may be due to changes in the protein structure, in post-translational 
modifications and in the expression of different isoforms heterogeneously occurring during 
tumoral transformation [11, 19, 67]. In fact, Western blot analysis on cell lysates obtained 
from patients specimens showed different expression of ADAM10 between Ser-ADAM10 + 
and Ser-ADAM10 – patients.  The expression of immature ADAM10 isoform (98 kDa) is 
predominantly expressed in Ser-ADAM10 + patients while its expression in Ser-ADAM10 – 
patients is low or absent. The overexpression of immature (non cleaved) inactive ADAM10 
in Crc patients might be due to its reduced processing in the Golgi compartment, resulting in 
a reduced expression of active ADAM10 in the surface membrane. Accordingly, the 
ADAM10 sheddase activity is reduced on the membrane of these cells, explaining the 
reduced HER2 ECD release and decreased expression of phosphorilated-ERK1/2 detected in 
these patients. Thus, the serological reactivity elicited by ADAM10 in Crc patients might 
report the overexpression of inactive ADAM10, in particular we might hypothesize that the 
specific sequence recognized by the auto-Abs might be an epitope within the non-cleaved 
prodomain. This might explain why purified IgG from Crc patients were not able to confirm 
in vitro the successful inhibition of the ADAM10 activity observed using commercial anti-
ADAM10 antibodies. The purified IgG were not able to recognize the specific epitope since 
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LoVo cells, as well as any living cell, do not express on the cell surface the inactive 
ADAM10 containing the prodomain, being the enzymatic precursor processed in 
intracellular compartment [76]. The intracellular localization in which the recognition and 
cleavage of ADAMs substrates occurs is still a matter of debate [75], however the surface 
form of ADAM10 appears to be processed while the majority of the proenzyme form of 
ADAM10 is found in the Golgi [76]. Nowadays it is not completely clear how antibody 
response against intracellular proteins occurs. Some mechanisms that allow intracellular 
peptides to trigger the immune response have already been described, such as chaperon-
mediated autophagy [68] and exosomes [69]. Moreover the aberrant tumor cell death is an 
accepted hypothesis in which the intracellular aberrant proteins are released from tumor cells 
[70, 71]. The knowledge of the modificated part of the TAA that is recognized by the auto-
Abs might be useful as therapeutic target but also to understand the possible secondary 
mechanism that is involved in the protein processes. 
 In conclusion, the presence of auto-Abs anti-ADAM10 may be a favourable 
prognosis biomarker for Crc patients at advanced stages of the disease that report an 
overexpression of inactive ADAM10 during the cell transformation and accordingly the 
reduce protein maturation lead to a decrease of its sheddase activity that decline the 
proliferative and invasive capacity of tumor cells.  Patients belonging to the same stage of 
the disease may evolve in different manner leading to different prognosis, depending on the 
autoantibody response that has been developed. Therefore, from the clinical point of view, 
the relevance of this auto-Abs provides information about the disease progression which is 
crucial in order to perform personal therapies, based on the immune response elicited against 
ADAM10, with the aim to suppress tumor or slow down its progression. 
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Figure 19. Schematic representation of our hypothesis. Ser-ADAM10 – patients present a normal expression 
of both active ADAM10 and inactive ADAM10 resulting in a physiological function of the protein which 
promote the progression of the disease in Crc patients. On the contrary, Ser-ADAM10 + patients show an 
overexpression of the inactive ADAM10 that elicit the immune response and is recognized by the auto-Abs, 
then the reduced expression of the active form of ADAM10 is responsible for the decrease in the activity of the 
protein and results in slowing of the disease progression. 
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5. MATERIALS & METHODS 
 
 
5.1. Sera and Tissue Samples 
 
 Samples were obtained following informed patient consent and after approval by the 
Institutional Ethical Committee. Sera were collected at the time of surgical resection from a 
cohort of 106 patients with Colorectal cancer (Crc), and from a control group (Cn) that 
included 91 healthy subjects and patients with non-tumoral pathologies. Crc patients with 
(Stage III and IV; n= 54) or without (Stage I and II; n= 52) infiltration in the regional lymph 
nodes were considered as separated subgroups in some analyses. Cohorts of sera from 
different tumors namely pancreatic carcinoma (Pc, n= 43), breast carcinoma (Brc, n= 35), B-
cell chronic lymphocytic leukemia (B-CLL, n= 53) and multiple myeloma (MM, n= 46) 
were also collected. The summary of the demographic and clinical features of the 
populations enrolled in the study and features of the single subjects of each group are 
reported in the Appendix. Tissue specimens from Crc tumor were frozen immediately after 
surgical removal and stored at -800C until use.  
 
5.2. Cell line and cell culture  
 
 The tumor cell line used in this study was LoVo metastatic Colon carcinoma 
(American Type Culture Collection, ATCC); the cells were grown in RPMI containing 10% 
fetal bovine serum (FBS), penicillin, and streptomycin, under standard conditions (370C, 5% 
CO2) in humidified incubator.  
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5.3. Serological screening on purified ADAM10: SDS-PAGE and Western 
blot analysis.   
 Recombinant purified extracellular domain of mouse recombinant ADAM10 
(Calbiochem), sharing 97% amino acid homology with human ADAM10, was resolved (200 
ng lane) by 10% acrylamide SDS-PAGE (Sodium Dodecyl Sulphate - PolyAcrylamide Gel 
Electrophoresis). Proteins were electrotransferred to nitrocellulose membrane that was cut 
vertically into strips that contained two lines of protein and blocked by incubation with fat-
free milk for 1 hour at room temperature. After that, each strip was incubated at 4°C over 
night with sera obtained from either patients or controls (1:5000 dilution). As secondary 
antibodies were used either goat anti-human IgG (Southern Biotechnology Associates, 
Birmingham, AL) or rabbit anti-goat (Dako Denmark) conjugated with horseradish 
peroxidase. The signals were developed by chemiluminescence substrate reaction by using 
ECL (GE-Healthcare) followed by autoradiography with film exposure. In order to quantify 
the sera reactivities, films were used for densitometric analysis. Images were acquired using 
a Personal SI Laser Densitometer (Molecular Dynamics), and the analysis of the optical 
density (OD) of sera reactivity was performed using Image Quant v.1 software (GE-
Healthcare). The signals were normalize with a positive control obtained by using a 
commercial anti-ADAM10 antibody (Goat anti-human ADAM10 Ectodomain Antibody. 
R&D Systems) tested in all experiments.  
 
5.4. HER2 ECD release assay by ELISA.  
 
 The quantification of HER2 ECD (p105) in both cell culture conditional medium and 
serum from patients and healthy subjects was measured by using cerb-B2/c-neu rapid format 
ELISA kit (Calbiochem).  
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 The ELISA kit was used to measured the HER2 ECD released in the conditioned 
medium of LoVo carcinoma cell line culture. Cells were seeded in 96-well plates at 5x103 
cells/well in 100 μl of RPMI supplemented with 10% FBS. Preliminary test experiment 
confirmed that the ELISA kit was not reactive against the possible presence of HER2 from 
the FBS. After 24 hours, the medium was replaced with or without the addition of antibodies 
(goat anti-ADAM10 antibody US Biological, goat anti-ADAM10 antibody R&D Systems, 
purified IgG from goat serum or purified IgG from Crc patient sera) at the concentrations 
indicated in individual experiments. Cells were cultivated for further 72 hours. Cell culture 
conditioned medium were removed, centrifuged to discard any cells and concentrated with 
centrifuge 50 kDa cut-off device filters (Amicon) before use in ELISA test.  
 Recombinant full length p195HER2/neu (p195) was used to generate the standard 
curve (0 ng/ml, 0.188 ng/ml, 0.375 ng/ml, 0.75 ng/ml and 1.5 ng/ml). The reaction volume 
for each sample and each standard was 100 μl/well. The ELISA assay was performed on 96 
well plates coated with mouse monoclonal HER2 antibody that recognizes the extracellular 
domain. The detector antibody, was a biotinylated mouse monoclonal anti-HER2 and the 
reactivity was revealed by streptavidin-peroxidase followed by the Substrate tetra-
methylbenzidine (TMB) addition. The color intensity, proportional to the HER2 ECD 
concentrations, was measured with a spectrophotometer adjusted at dual wavelengths of 
450/595 nm, within 30 min from adding the Stop Solution.  All reagents are included in the 
ELISA kit. 
 The ELISA kit was also used to measure the HER2 ECD released in the sera from 
Crc patients and control subjects.  
 All samples and standards were diluted (1:20) using Sample diluent and were 
assayed in triplicate. 
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5.5. Protein expression in Primary Tumor Tissues. 
 
 Tissue species from -800C storage were immerse in liquid nitrogen and mechanically 
broken in a Eppendorf tube by using a dedicated pestle. Then extraction buffer (50mM Tris 
HCl pH 7.4, 150mM NaCl, 1%Triton, 1mM EDTA) containing protease (1:100 protease 
inhibitors cocktail SIGMA) and phosphatase inhibitor (1mM NaF, 2mM Na3VO4) was added 
and samples were incubated in ice for 20 min. After centrifugation (16000g, 20 min, 40C) 
the supernatant was recovered and solubilized protein concentration was determined by 
Bradford method (Bio-Rad Protein Assay) using bovine serum albumin (BSA) as standard. 
Total proteins from each sample (15μg) were loaded on 10% acrylamide gel SDS-PAGE. 
Once the electrophoresis is finished, proteins were electro transferred to nitrocellulose 
membrane and blocked by incubation with BSA for 1 hour at room temperature. Then, the 
membranes were incubated over night at 40C with the following primary antibodies: mouse 
anti-ADAM10 monoclonal antibody (Abcam), rabbit anti-HER2 polyclonal antibody 
(Abcam), rabbit anti-phospho-p44/42 MAPK (ERK1/2) antibody (Cell signaling), rabbit 
anti-total p44/42 MAPK (ERK1/2) antibody (Cell signaling), mouse anti-β-actin 
monoclonal antibody (Sigma). As secondary antibodies were used goat anti-rabbit Ig and 
rabbit anti-mouse Ig conjugated with horseradish peroxidase (Dako Denmark). The protein 
loading and transfer was normalized by Ponceau S (Sigma) staining and by actin 
immunoblotting. 
 
5.6. Immunoglobulin G purification from Crc patient sera and goat serum. 
 Total IgG were purified from sera of colon cancer patients, either positive or 
negative for the presence of anti-ADAM10 Abs, and from goat serum, the latter as to be 
used as negative control of commercial goat anti-ADAM10 antibodies.  IgG purification was 
performed by using Recombinant Protein G Agarose (rProtein G Agarose; Invitrogen).  
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According to the IgG binding capacity of rProtein G Agarose (20mg/ml) and the IgG 
concentration range in human (7.5-22 mg/ml in human and 18-24 mg/ml in goat), 200 μl of 
dry beads were used to purified IgG from 250 μl of serum.  After washing with phosphate 
buffered saline (PBS) (3x) the dry beads were mixed with 250μl of serum and the volume 
was adjusted to 1 ml with PBS. The mixture was left to incubate for 24 hours at 4°C under 
gently shacking. The supernatant was then removed, the beads were washed 3 times with 1 
ml of PBS, the bound IgGs were eluted by incubation with 1ml of Elution Buffer (0.1 M 
Glycine HCL, pH 2.6) at 200C for 10 min. The pH was then adjusted to about pH 7.0 by the 
addition of 16.7 μl (1:60 v/v) of Tris 1M, the beads were pelleted by centrifugation (2 
minutes, 13000 rcf, 4°C) and the eluted IgGs were concentrated using centrifugal 100kDa 
cut-off device filters (Amicon) (20 min, 13000 rcf, 4°C). By using the same device, the 
buffer in which the purified IgG were resuspended, was exchanged and concentrated to 
reach a final volume of 35 μl in PBS for each samples. Total IgG concentration was 
determined by Bradford method (Bio-Rad Protein Assay) using BSA as standard. 
 
5.7. In vitro wound healing assay. 
 
 LoVo cells were seeded in 12–well plates at 5x105 cells/well in 1 ml of RPMI 
containing 10% FBS and cultured overnight as to reach cell confluence. The next day, a 
straight scratch was done by using a pipette tip at right angle with the plate in order to 
maintain the width wound uniform. Cells were washed with PBS and subsequently 500 ul of 
medium containing either 10 μg/ml of commercial goat anti-ADAM10 antibody US 
Biological or 10 μg/ml of IgG purified from Crc patients. Medium with 10 μg/ml of purified 
IgG from goat serum was tested as control. The media were replaced by fresh medium 
containing the same treatment concentrations every 24 hours. To monitor cell migration, 
images (10x objective) of the wound closure were taken at times 0 and 72 hours (Leica 
Materials & Methods 
53 
 
DFC300 FX, Wetzlar, Germany) using a 10x objective. The streaks of each plate were 
photographed on three different areas and the wound area was measured with the 
informatics software ImageJ (Imaje Processing And Analysis in Java). The closing 
percentage after 72 hours was calculated with respect to Time 0 for each condition.  
 
5.8. Statistical analysis  
 
 Each serum was tested twice on purified ADAM10 and the reactivity was quantified 
by comparing normalized OD in patients and controls. After background subtraction 
evaluated for every sera, OD values were normalized to the reactivity of the commercial 
anti-ADAM10 obtained in the same film exposures. Statistical analysis of categorical data 
(positive or negative sera immunoreactivity) was performed by 2x2 contingency table 
analysis using Fisher’s exact test and two-tailed p-value. Wound healing measures were 
evaluated using unpaired Student’s t-test with two-tailed p value for the comparison of two 
means with standard deviation. In the case of non-Gaussian distribution (intensity of 
immunoreactivity as arbitrary unit of OD and HER2 ECD release concentration in sera), 
data were evaluated using Mann-Whitney U test to compare differences between two 
independent groups and the analysis of variance was performed using the Kruskal-Wallis 
test. The follow-up of Crc patients was evaluated by generating Kaplan-Meier survival 
curves using tumor-relapse, presence of metastasis and patient death as end-point; survival 
curves were compared using the log-rank test. The receiver operating characteristic curve 
(ROC) was used to define the threshold value for OD that gave the better ratio between 
sensitivity and specificity. Correlation analysis was evaluated using Spearman’s rank 
coefficient. Statistical analysis were performed using GraphPad Prism V5 software 
(GraphPad Inc.), in all analysis p<0.05 was considered to be statistically significant.  
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7. APPENDIX 
 
 
Ptz # Gender Age Stage (category)b normalized OD 237.2 OD cut-off Follow-up
1 m 53 Stg I (T1N0M0) 228,52 - A 24
2 f 57 Stg I (T1N0M0) 1157,94 + A 52
3 f 72 Stg I (T1N0M0) 819,881018 + A47
4 m 41 Stg I (T1N0M0) 85,368708 - A46
5 m 71 Stg I (T1N0M0) 399,889648 + A6
6 f 60 Stg I (T1N0M0) 1493,091095 + A43
7 m 65 Stg I (T1N0M0) 625,581678 + A41
8 m 78 Stg I (T2N0M0) 152,418569 - A47
9 f 54 Stg I (T2N0M0) 1044,74624 + -
10 m 77 Stg I (T2N0M0) 1,048112 - A26
11 f 85 Stg I (T2N0M0) 1211,657354 + -
12 f 73 Stg I (T2N0M0) 408,694948 + A45
13 f 70 Stg I (T2N0M0) 137,490284 - A44
14 f 62 Stg I (T2NxM0) 1293,028738 + A43
15 m 85 Stg I (T2N0M0) 284,229006 + A37
16 m 50 Stg I (T2N0M0) 243,319154 + A42
17 m 57 Stg I (T2N0M0) 159,6 - A 60
18 m 83 Stg I (T2N0M0) 242,94 + A 33
19 m 73 Stg I (T2N0M0) 84,55 - A 34
20 f 61 Stg I (T2N0M0) 46,34 - A 53
21 m 71 Stg I (T2N0M0) 122,09 - A 29
22 m 66 Stg I (T2N0M0) 390,35 + -
23 f 73 Stg II (T3N0M0) 364,93 + A 34
24 m 73 Stg II (T3N0M0) 785,73 + M 6 +32
25 f 60 Stg II (T3N0M0) 117,89 - A 63
26 f 53 Stg II (T3N0M0) 71,82 - A 64
27 m 84 Stg II (T3N0M0) 14,83 - A 60
28 m 80 Stg II (T3N0M0) 182,24 - A 59
29 f 57 Stg II (T3N0M0) 372,12 + A 59
30 m 81 Stg II (T3N0M0) 529,93 + A 58
31 m 61 Stg II (T3N0M0) 565,57 + A 61
32 f 51 Stg II (T3N0M0) 455,41 + A 73
33 f 63 Stg II (T3N0M0) 569,43 + A 60
34 f 62 Stg II (T3N0M0) 596,5 + A 59
35 f 75 Stg II (T3N0M0) 707,75 + A 64
36 m 59 Stg II (T3N0M0) 127,313061 - -
37 f 77 Stg II (T3N0M0) 675,954563 + A47
38 f 72 Stg II (T3N0M0) 70,683728 - -
39 m 84 Stg II (T3N0M0) 478,155141 + A45
40 m 64 Stg II (T3N0M0) 1068,601845 + A25
41 f 79 Stg II (T3N0M0) 458,15559 + A45
42 f 74 Stg II (T3N0M0) 398,354127 + A45
43 m 80 Stg II (T3N0M0) 1047,594678 + A44
44 m 78 Stg II (T3N0M0) 551,133175 + A44
45 f 78 Stg II (T3N0M0) 3003,212479 + A43
46 f 96 Stg II (T3N0M0) 773,399173 + A43
47 f 52 Stg II (T3N0M0) 279,522874 + A43
48 m 72 Stg II (T3N0M0) 267,584664 + A41
49 m 74 Stg II (T3N0M0) 2098,17 + A 38
50 f 70 Stg II (T4N0M0) 25,42 - M 10 + 28
Supplemental Materials Table S1
Demographic and clinical features of the Colorectal cancer patients.
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51 m 82 Stg II (T4N0M0) 1169,88 + A 64
52 m 59 Stg II (T4N0M0) 691,37 + A 59
53 m 68 Stg III (T2N1M0) 301,18 + -
54 f 55 Stg III (T3N1M0) 199,54 - M 0 +23
55 f 61 Stg III (T3N1M0) 178,14 - R 28 M 28 A38
56 f 68 Stg III (T3N1M0) 518,75 + A 63
57 f 69 Stg III (T3N1M0) 548,63 + M 17
58 m 79 Stg III (T3N1M0) 674,81 + M 34
59 m 80 Stg III (T3N1M0) 998,23 + R 11 M 35
60 m 73 Stg III (T3N1M0) 702,51 + M 55 A55
61 m 67 Stg III (T3N1M0) 843,53 + M 3 +21
62 m 66 Stg III (T3N1M0) 1237,61 + A 33
63 f 74 Stg III (T3N1M0) 949,55 + A 62
64 m 90 Stg III (T3N1M0) 1470,67 + M 10 + 30
65 m 47 Stg III (T3N1M0) 648,035927 + R43 A47
66 m 70 Stg III (T3N1M0) 1818,219038 + A45
67 m 49 Stg III (T3N1M0) 695,339305 + A45
68 m 70 Stg III (T3N1M0) 199,52876 - R16 A45
69 m 73 Stg III (T3N1M0) 352,800146 + A44
70 f 80 Stg III (T3N1M0) 767,002277 + R23 +23 
71 f 65 Stg III (T3N1M0) 308,258811 + A41
72 f 48 Stg III (T4N1M0) 3,91 - M 23 A31
73 f 52 Stg III (T4N1M0) 369,47 + -
74 f 83 Stg III (T2N2M0) 54,65 - M 26 +30
75 m 58 Stg III (T2N2M0) 766,55 + -
76 m 81 Stg III (T3N2M0) 59,94 - M 0 +14
77 m 44 Stg III (T3N2M0) 510,18 + -
78 f 73 Stg III (T3N2M0) 644,22 + M 2 +12
79 m 64 Stg III (T3N2M0) 334,4 + A 37
80 m 69 Stg III (T3N2M0) 261,01 + A 53
81 f 44 Stg III (T3N2M0) 587,98 + M 3 A 35
82 m 66 Stg III (T3N2M0) 834,34 + M 3 +27
83 m 76 Stg III (T4N2M0) 351,84 + M 6 +10
84 m 45 Stg III (T4N2M0) 757,57 + M 0 +28
85 f 77 Stg III (T4N2M0) 511,99 + A 29
86 f 69 Stg III (T4N1M0) 595,119576 + A47
87 f 77 Stg III (T4N1M0) 3213,929626 + A46
88 f 70 Stg III (T3N2M0) 875,972364 + R14 A43
89 f 67 Stg III (T3N2M0) 350,169951 + A41
90 m 56 Stg III (T3N2M0) 240,406793 + A40
91 m 64 Stg IV (TxNxM1) 637,286342 + M0 R29 +29
92 m 45 Stg IV (T3N0M1) 970,278044 + M0 A47
93 m 37 Stg IV (T3N0M1) 256,704197 + M0 M10 +27
94 m 55 Stg IV (T1N1M1) 99,392811 - M0 A25
95 f 61 Stg IV (T3N1M1) 695,887341 + M0 R15
96 f 72 Stg IV (T3N1M1) 192,70291 - M0 R7 A23
97 m Stg IV (T3N1M1) 94,871724 - M0 R29 R37 A43
98 m 67 Stg IV (T4N1M1) 2985,066551 + M0 R26 A43
99 f 72 Stg IV (T4N1M1) 94,929794 - M0 +28
100 m 75 Stg IV (T3N2M1) 125,844697 - M0 R6 +26
101 f 60 Stg IV (T4N1M1) 319,54 + M0 R14 M16 A24
102 f 65 Stg IV (T4N2M1) 303,44 + M 0 +15
103 m 74 Stg IV (T4N2M1) 941,9 + M 0 +8
104 f 66 Stg IV (metas b) 962,58 + M 0 +6
105 m 66 Stg IV (metas ) 109,39 - M 0 R 10 +17
106 m 57 Stg IV (metas) 479,18 + M 0 +8
 a = staging and category of colon carcinoma according  to TNM classifications. UICC, tumor, nodes, metastases. 
T1-T4, invasive tumors (T1, submucosa; T2, tunica muscularis; T3, subserosa; T4, peritoneum or other organs).
M0, no distant metastases; M1, distant metastasis;
Stage I (T1-2, N0, M0), Stage II (T3-4, N0, M0), Stage III (T1-4, N1-2, M0), Stage IV (any T, any N, M1).
b = liver metastasis of colon carcinoma. m: male; f: female. OD= optical density (arbitrary units); 
 +, - = positive and negative reactivity using 237.2 OD cut-off.
A = alive; M= metastasis; R= relapse; += dead. 
 N0, no malignant regional lymphnodes; N1, 1-3 regional lymphnodes metastases; N2, >4 regional lymphnode metastases. 
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Ptz # Gender Age Stage (category)b normalized OD 237.2 OD cut-off
1 m 80 Stg I (T2N0M0) 227,6565312 -
2 m 49 Stg II (T3N0M0) 290,006681 +
3 m 61 Stg II (T3N0M0) 2941,625288 +
4 m 65 Stg II (T3N0M0) 268,6080692 +
5 m 55 Stg II (T3N0M0) 319,1174562 +
6 m 66 Stg II (T2N0M0) 2032,10902 +
7 m 65 Stg II (T3N0M0) 240,1435598 +
8 f 54 Stg II (T3N0M0) 1972,322728 +
9 f 75 Stg II (T3N0M0) 305,1569973 +
10 m 62 Stg II (T3N0MX) 129,6137602 -
11 m 71 Stg II (T3N0M0) 139,7745274 -
12 f 64 StgII(T3N0M0) 75,86736809 -
13 f 50 StgII (T3N0M0) 448,8767779 +
14 f 77 Stg III (T2N1M0) 430,6587305 +
15 m 66 Stg III (T3N1MX) 1023,285501 +
16 m 60 Stg III (T3N1MX) 273,012504 +
17 m 66 Stg III (T3N1M0) 1131,161439 +
18 f 80 Stg III (T3N1M0) 1309,252755 +
19 m 77 Stg III (T3N1M0) 156,7990702 -
20 m 65 Stg III (Npositivo) 1445,984434 +
21 f 53 Stg III (T3N1M0) 341,6848165 +
22 m 64 Stg III (T3N1M0) 544,3897833 +
23 f 69 Stg III (T3N1M0) 313,4547039 +
24 f 59 Stg III (T3N1M0) 121,6335325 -
25 f 77 Stg III (T3N1M0) 582,5253811 +
26 f 72 Stg III (T3N1M0) 385,2381419 +
27 m 84 Stg III (Npositivo) 80,17356146 -
28 f 64 Stg III (T3N1M0) 122,7571674 -
29 m 79 Stg III (T3N1M0) 267,215188 +
30 f 74 Stg III (T3N1M0) 217,1359626 -
31 m 80 Stg III (T3N1M0) 1561,809321 +
32 f 66 Stg III (T4N1M0) 190,1762314 -
33 f 74 Stg III (T2N0M1) 336,5519985 +
34 m 75 StgIII(T4N1M0) 46,05253594 -
35 f 72 StgIII(T4N1) 2124,287794 +
36 f 46 StgIII(T4N1) 3058,137141 +
37 m 50 StgIII(T4N1) 52,02744853 -
38 m 74 Stg IV (T4NXM1) 409,4999082 +
39 m 74 Stg IV (M1) 345,3794828 +
40 f 65 Stg IV (M1) 10471,13735 +
41 f 72 Stg IV (T4M1) 1695,106047 +
42 m 69 Stg IV (T2N0M1) 348,9650761 +
43 f 51 Stg X (T4NXMX) 265,700557 +
 a = staging and category of colon carcinoma according  to TNM classifications. UICC, tumor, nodes, metastases. 
T1-T4, invasive tumors (T1, submucosa; T2, tunica muscularis; T3, subserosa; T4, peritoneum or other organs).
M0, no distant metastases; M1, distant metastasis;
Stage I (T1-2, N0, M0), Stage II (T3-4, N0, M0), Stage III (T1-4, N1-2, M0), Stage IV (any T, any N, M1).
b = liver metastasis of colon carcinoma. m: male; f: female. OD= optical density (arbitrary units); 
 +, - = positive and negative reactivity using 237.2 OD cut-off.
 anti-ADAM 10 reactivity 
Supplemental Materials Table S2
Demographic and clinical features of the Pancreas cancer patients 
N0, no malignant regional lymphnodes; N1, 1-3 regional lymphnodes metastases; N2, >4 regional lymphnode metastases. 
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Ptz # Gender Age Stage (category)b normalized OD 237.2 OD cut-off
1 f 41 T1N0G2M0 106,66 -
2 f 41 T1bN0G3M0 106,80 -
3 f 48 T2N0G3M0 114,63 -
4 f 50 TisN0G2M0 336,46 +
5 f 47 T1bN0G2M0 148,25 -
6 f 61 T1cN0G2M0 128,19 -
7 f 51 T2N0G3M0 402,57 +
8 f 65 T1cN0G2M0 461,61 +
9 f 66 TisN0G2M0 35,86 -
10 f 68 T1cN0G1M0 345,60 +
11 f 71 T1cN1aG3M0 211,10 -
12 f 51 T1cN1G1M0 396,88 +
13 f 50 T4NXG1M0 336,67 +
14 f 67 T1cN0g2M0 466,06 +
15 f 35 T2 N0 112,96 -
16 f 29 T2 N1 172,04 -
17 f 48 T1  N0 471,54 +
18 f 59 T1 N0 387,47 +
19 f 43 T3 N1 319,02 +
20 f 42 T1 N1 428,27 +
21 f 42 T1 N0 302,12 +
22 f 64 T1 N0 540,44 +
23 f 58 T1 N0 1199,61 +
24 f 36 T1 N0 1174,86 +
25 f 69 T1 N0 370,80 +
26 f 62 T1 N0 645,55 +
27 f 46 T2 N0 706,35 +
28 f 40 T2 N0 459,58 +
29 f 52 T1 N0 706,17 +
30 f 62 T1 N2 513,05 +
31 f 50 T2 N0 274,06 +
32 f 39 T2 N0 663,65 +
33 f 44 T1 N1 232,55 -
34 f 46 T3 N1 194,63 -
35 f 60 T1 N1 1390,39 +
 a = staging and category of colon carcinoma according  to TNM classifications. UICC, tumor, nodes, metastases. 
T1-T4, invasive tumors (T1, submucosa; T2, tunica muscularis; T3, subserosa; T4, peritoneum or other organs).
M0, no distant metastases; M1, distant metastasis;
Stage I (T1-2, N0, M0), Stage II (T3-4, N0, M0), Stage III (T1-4, N1-2, M0), Stage IV (any T, any N, M1).
b = liver metastasis of colon carcinoma. m: male; f: female. OD= optical density (arbitrary units); 
 +, - = positive and negative reactivity using 237.2 OD cut-off.
Supplemental Materials Table S3
Demographic and clinical features of the Breast cancer patients 
 anti-ADAM 10 reactivity 
N0, no malignant regional lymphnodes; N1, 1-3 regional lymphnodes metastases; N2, >4 regional lymphnode metastases. 
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Demographic and clinical features of the B-cell chronic lymphocytic leukemia patients 
Ptz # Gender Age normalized OD 237.2 OD cut-off
1 m 63 923,19 +
2 m 78 117,30 -
3 m 60 185,70 -
4 m 75 257,74 +
5 m 67 194,92 -
6 f - 489,89 +
7 m 79 754,92 +
8 m 58 47,42 -
9 m 57 46,78 -
10 m 64 219,63 -
11 f 79 23,78 -
12 m - 575,67 +
13 m 71 232,24 -
14 m - 283,72 +
15 m 60 256,52 +
16 m 65 740,21 +
17 f - 507,66 +
18 m 75 600,33 +
19 f 42 273,08 +
20 m 75 519,81 +
21 m 68 150,15 -
22 m 66 252,71 +
23 m 69 361,91 +
24 f 55 56,68 -
25 m 73 114,10 -
26 m 46 282,75 +
27 f 71 759,50 +
28 f 60 993,82 +
29 m 60 37,08 -
30 f 54 617,99 +
31 m 82 88,86 -
32 m 56 797,55 +
33 f 72 252,95 +
34 m 78 201,21 -
35 f 67 11,53 -
36 m 53 401,19 +
37 f 76 38,14 -
38 m 46 85,79 -
39 f 73 152,59 -
40 f 80 83,24 -
41 m 40 271,15 +
42 m 55 171,23 -
43 f 55 178,88 -
44 m 61 774,54 +
45 f 69 249,43 +
46 f 49 424,39 +
47 f 76 552,25 +
48 m 87 418,18 +
49 f 72 67,13 -
50 m 70 138,61 -
51 f 71 178,86 -
52 m 79 370,21 +
53 m 55 107,19 -
m: male; f: female. OD= optical density (arbitrary units); 
 +, - = positive and negative reactivity using 237.2 OD cut-off.
Supplemental Materials Table S4
 anti-ADAM 10 reactivity 
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Ptz # Gender Age normalized OD 237.2 OD cut-off
1 f 61 352,04 +
2 f 61 814,84 +
3 m 68 858,03 +
4 m 72 542,32 +
5 f 67 351,51 +
6 f 67 385,60 +
7 f 78 133,79 -
8 f 66 813,58 +
9 f 72 38,60 -
10 f 58 732,18 +
11 f 73 60,00 -
12 m 61 299,16 +
13 m 61 126,71 -
14 f 70 11,46 -
15 m 51 118,42 -
16 m 52 111,48 -
17 f 73 125,78 -
18 m 67 168,84 -
19 f 68 442,64 +
20 f 73 43,27 -
21 m 80 71,02 -
22 m 40 108,82 -
23 f 66 40,06 -
24 m 74 440,41 +
25 f 77 242,86 +
26 f 72 22,86 -
27 f 70 22,15 -
28 f 64 262,85 +
29 f 66 415,11 +
30 m 73 94,17 -
31 m 87 40,59 -
32 f 58 565,01 +
33 m 45 1281,05 +
34 f 67 76,56 -
35 m 55 378,01 +
36 m 75 1527,50 +
37 f 40 186,86 -
38 m 64 307,43 +
39 m 77 26,56 -
40 f 81 10,88 -
41 f 68 20,03 -
42 m 84 426,79 +
43 m 66 56,43 -
44 f 73 155,96 -
45 m 58 329,76 +
46 m 52 88,70 -
m: male; f: female. OD= optical density (arbitrary units); 
 +, - = positive and negative reactivity using 237.2 OD cut-off.
 anti-ADAM 10 reactivity 
Supplemental Materials Table S5
Demographic and clinical features of the Multiple Myeloma patients 
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Supplemental Materials Table S6
Subject # Gender Age Clinical status normalized OD 237.2 OD cut-off
1 f 79 inguinal hernia 2,48 -
2 f 59 endometrial polyp 3,13 -
3 f 68 hepatic cyst 365,42 +
4 m 44 healthy 39,74 -
5 m 45 healthy 39,74 -
6 f 61 diverticulosis 261,29 +
7 f 73 cataract 80,05 -
8 m 71 cataract 25,93 -
9 f 76 rectocele 78,27 -
10 f 58 hyperparathyroidism 110,31 -
11 m 69 cirrhosisr 103,69 -
12 m 86 diabetes 420,81 +
13 m 69 rectal prolapse 199,16 -
14 m 73 inguinal hernia 323,74 +
15 m 81 pulmonary embolism 125,02 -
16 f 43 healthy 177,42 -
17 f 76 diabetes 130,37 -
18 f 27 healthy 176,83 -
19 f 58 healthy 125,49 -
20 m 69 healthy 176,11 -
21 m 73 healthy 228,38 -
22 f 50 cervical ectropion 351,28 +
23 f 58 healthy 306,22 +
24 f 57 thyroid goiter 233,93 -
25 f 70 diverticulosis 233,29 -
26 m 79 healthy 407,87 +
27 m 81 healthy 473,58 +
28 f 73 healthy 312,29 +
29 f 64 bronchial asthma 1,6 -
30 f 67 healthy 442,75 +
31 m 77 inguinal hernia 186,24 -
32 f 26 healthy 477,16 +
33 m 91 hemorroiditis 27,47 -
34 f 62 healthy 558,21 +
35 f 73 diabetes 515,14 +
36 f 30 healthy 126,18 -
37 f 67 healthy 734 +
38 m 60 healthy 127,21 -
39 f 61 cholecystitis 553,93 +
40 m 74 healthy 202,49 -
41 m 57 healthy 888,54 +
42 m 76 healthy 262,20 +
43 f 65 healthy 58,78 -
44 m 82 healthy 91,88 -
45 m 53 healthy 618,80 +
 anti-ADAM 10 reactivity
Demographic and clinical features of the Control subjects 
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46 m 76 healthy 353,64 +
47 m 66 healthy 183,68 -
48 f 77 healthy 220,25 -
49 m 76 healthy 85,67 -
50 m 67 healthy 86,21 -
51 m 52 healthy 528,48 +
52 m 69 healthy 827,93 +
53 m 72 healthy 968,50 +
54 f 88 healthy 226,19 -
55 f 70 healthy 169,61 -
56 m 67 healthy 60,88 -
57 f 67 healthy 303,60 +
58 m 72 healthy 228,13 -
59 m 61 healthy 662,79 +
60 f 51 healthy 3,43 -
61 f 59 healthy 202,44 -
62 f 53 healthy 39,32 -
63 f 60 healthy 144,45 -
64 f 75 healthy 160,31 -
65 f 57 healthy 195,97 -
66 f 76 healthy 173,15 -
67 f 91 healthy 204,18 -
68 f 57 healthy 446,88 +
69 f 52 healthy 566,61 +
70 f 63 healthy 3,75 -
71 f 92 healthy 221,09 -
72 f 55 healthy 42,94 -
73 f 68 healthy 157,77 -
74 f 89 healthy 175,08 -
75 f 78 healthy 214,03 -
76 m 45 healthy 431,76 +
77 m 32 healthy 102,86 -
78 f 68 healthy 533,68 +
79 f 51 healthy 150,10 -
80 f 55 healthy 552,64 +
81 m 45 healthy 108,71 -
82 f 48 healthy 370,80 +
83 f 44 healthy 489,91 +
84 f 69 healthy 112,27 -
85 m 45 healthy 84,39 -
86 m 54 healthy 615,50 +
87 f 70 healthy 332,42 +
88 f 34 healthy 290,05 +
89 m 49 healthy 137,49 -
90 f 59 healthy 104,45 -
91 m 71 healthy 159,56 -
m: male; f: female. OD= optical density (arbitrary units); 
 +, - = positive and negative reactivity using 237.2 OD cut-off.
